New insider Durocher John claimed ownership of 1,928 shares (SEC Form 3)
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 11/16/2025 |
3. Issuer Name and Ticker or Trading Symbol
CALIX, INC [ (CALX) ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 1,928 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (1) | 03/24/2033 | Common Stock | 200,000 | $51.83 | D | |
| Stock Option (right to buy) | (2) | 03/24/2033 | Common Stock | 42,555 | $51.83 | D | |
| Stock Option (right to buy) | (3) | 02/08/2034 | Common Stock | 107,775 | $34.26 | D | |
| Stock Option (right to buy) | (4) | 02/08/2034 | Common Stock | 56,350 | $34.26 | D | |
| Stock Option (right to buy) | (5) | 01/31/2035 | Common Stock | 195,000 | $39.68 | D | |
| Stock Option (right to buy) | (6) | 01/31/2035 | Common Stock | 195,000 | $39.68 | D | |
| Explanation of Responses: |
| 1. 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 125,000 shares subject to the option grant are fully vested and exercisable. |
| 2. 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 26,597 shares subject to the option grant are fully vested and exercisable. |
| 3. 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 47,151 shares subject to the option grant are fully vested and exercisable. |
| 4. 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 17,622 shares subject to the option grant are fully vested and exercisable. |
| 5. 25% of these stock options will vest on the first anniversary of the grant date. Thereafter, the remainder of these stock options will vest quarterly in substantially equal installments over the next 36 months, subject to Reporting Person's continued service through each vesting date. |
| 6. The nonqualified stock option award shall vest: (i) as to 25% of the shares of common stock subject to the stock option award, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the stock option award, quarterly in equal installments over 36 months from January 31, 2026, subject to the reporting person's continued employment with Calix through the applicable vesting dates. |
| Remarks: |
| /s/ Tom Gemetti as Attorney-in-Fact for John Durocher | 11/25/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||